Ron Piervincenzi Named Next CEO of USP
Ron Piervincenzi to assume leadership of the United States Pharmacopeial Convention on Feb. 1, 2014.
The Board of Trustees of the United States Pharmacopeial Convention (USP) today announced that Ron Piervincenzi will become the chief executive officer of USP and chair of USP’s standards-setting body, the Council of Experts. Piervincenzi will assume these responsibilities Feb. 1, 2014.
“I am excited and honored to lead USP’s mission to improve global health,” said Piervincenzi. “This is an outstanding organization doing life-changing work around the world, and I look forward to focusing the collective energy, expertise and knowledge of USP’s global volunteers and staff on the challenges of the future.”
“In Dr. Piervincenzi we have found an outstanding new leader for USP, which has seen unprecedented growth over the past several years,” said USP Board of Trustees Chair, Thomas R. Temple, R.Ph., M.S. “I am excited about Dr. Piervincenzi’s commitment to the next phase of USP’s unique mission to develop and promote cutting edge global standards for pharmaceuticals, food, and dietary supplements.”
Piervincenzi was a partner and leader in McKinsey & Company's Global Pharmaceutical and Medical Products Practice for 12 years where, among other responsibilities, he launched McKinsey's global drug safety, medical and regulatory service line. Dr. Piervincenzi earned an MS and PhD from Duke University in Biomedical Engineering with research focused on protein engineering.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
